AstraZeneca PLC (AZN)
|Net Income (ttm)||2.04B|
|Ex-Dividend Date||Aug 11, 2022|
|Day's Range||62.57 - 63.39|
|52-Week Range||52.65 - 72.12|
|Price Target||74.78 (+19.06%)|
|Earnings Date||Feb 9, 2023|
AstraZeneca PLC, a biopharmaceutical company, focuses on the discovery, development, manufacturing, and commercialization of prescription medicines. Its marketed products include Calquence, Enhertu, Faslodex, Imfinzi, Iressa, Koselugo, Lumoxiti, Lynparza, Orpathys, Tagrisso, and Zoladex for oncology; Brilinta/Brilique, Bydureon/Byetta, BCise, Byetta, Crestor, Evrenzo, Farxiga/Forxiga, Komboglyze/Kombiglyze XR, Lokelma, Onglyza, Qtern, and Xigduo/Xigduo XR for cardiovascular, renal, and metabolism diseases; Bevespi Aerosphere, Breztri Aerosphere... [Read more]
In 2021, AstraZeneca's revenue was $37.42 billion, an increase of 40.58% compared to the previous year's $26.62 billion. Earnings were $112.00 million, a decrease of -96.50%.Financial Statements
According to 39 analysts, the average rating for AZN stock is "Buy." The 12-month stock price forecast is $74.78, which is an increase of 19.06% from the latest price.
The court ruled that drugmakers can limit their shipments of federally-discounted drugs to pharmacies, in a blow to hospitals and clinics.
TROPION-Lung07 Phase 3 Trial Initiated to Evaluate Datopotamab Deruxtecan in Combination with Pembrolizumab in Patients with Previously Untreated Metastatic Non-Small Cell Lung Cancer
TOKYO & BASKING RIDGE, N.J.--(BUSINESS WIRE)--Daiichi Sankyo (TSE: 4568) today announced that the first patient has been dosed in the global, randomized TROPION-Lung07 phase 3 trial evaluating datop...
AstraZeneca's (AZN) Evusheld is no longer authorized for use in the United States after laboratory data showed that it does not neutralize Omicron subvariants.
Mergers and acquisitions are a normal part of business, but 2023 has already presented many opportunities across the biotech industry. The M&A surge seems to be driven by two major transactions: the $...
FDA withdraws Covid antibody treatment Evusheld because it's not effective against 93% of subvariants
Many take Evusheld as an additional layer of protection because the vaccines do not trigger a strong immune response for them.
AstraZeneca AZN, -1.32% AZN, -1.54% said Thursday that the Food and Drug Administration is no longer allowing healthcare providers to prescribe Evusheld, a therapy authorized for pre-exposure prophyla...
ENHERTU® Approved in the EU as the First HER2 Directed Therapy for Patients with HER2 Low Metastatic Breast Cancer
TOKYO & MUNICH--(BUSINESS WIRE)--Daiichi Sankyo (TSE: 4568) and AstraZeneca's (LSE/STO/Nasdaq: AZN) ENHERTU® (trastuzumab deruxtecan) has been approved in the European Union (EU) as monotherapy indi...
Thermo Fisher Scientific Partners with AstraZeneca to Develop Solid Tissue and Blood-Based Companion Diagnostic Test for Tagrisso
CARLSBAD, Calif.--(BUSINESS WIRE)--As part of a global, multiyear agreement, Thermo Fisher Scientific today announced it is working with AstraZeneca to develop a solid tissue and blood-based compani...
WILMINGTON, Del.--(BUSINESS WIRE)--AstraZeneca is commencing today, through a subsidiary, a tender offer to purchase all outstanding shares of CinCor Pharma, Inc. (CinCor), for $26 per share in cash...
AstraZeneca chair: Health care systems around the world can benefit from investment in technology
Leif Johansson, chairman at AstraZeneca, speaks to CNBC's Karen Tso at Davos 2023.
AstraZeneca AZN, +0.99% AZN, -0.27% said Wednesday that the Food and Drug Administration approved a new therapy that can be used to treat or prevent bronchoconstriction in adults with asthma. Thee com...
AstraZeneca's (AZN) CinCor Pharma buyout is going to add blood pressure drug baxdrostat to its cardiorenal pipeline.
NEW YORK , Jan. 9, 2023 /PRNewswire/ -- Weiss Law is investigating possible breaches of fiduciary duty and other violations of law by the board of directors of CinCor Pharma, Inc. ("CinCor" or the "Co...
European drugmakers on Monday announced a trio of deals around a billion dollars each to buy U.S.-listed biopharmas at hefty premiums.
AstraZeneca said the deal, expected to close in the first quarter of 2023, will bolster its cardiorenal pipeline
AstraZeneca PLC said Monday that it has agreed to buy CinCor Pharma, Inc., acquiring global rights to the latter's baxdrostat cardiorenal drug for an upfront transaction value of around $1.3 billion.
AstraZeneca said on Monday it will buy U.S.-based clinical-stage biopharmaceutical firm CinCor Pharma Inc in a deal valued at about $1.8 billion to strengthen its pipeline of heart and kidney drugs.
The Food and Drug Administration late Friday said that AstraZeneca Plc's AZN, +1.42% COVID-19 drug Evusheld may not provide protection against developing the illness in people exposed to XBB.1.5, one ...
The FDA's decision on AstraZeneca (AZN)/Sanofi's (SNY) regulatory filing, seeking approval for using their RSV antibody in all infants, is expected in third-quarter 2023.
CHICAGO--(BUSINESS WIRE)--Tempus, a leader in artificial intelligence and precision medicine, today announced a prospective study (NCT05257551), in collaboration with AstraZeneca (LSE/STO/Nasdaq: AZ...
ENHERTU® Type II Variation Application Validated by EMA for the Treatment of HER2 Mutant Metastatic Non-Small Cell Lung Cancer
TOKYO & MUNICH--(BUSINESS WIRE)--Daiichi Sankyo (TSE: 4568) today announced that the European Medicines Agency (EMA) has validated the Type II Variation application for ENHERTU® (trastuzumab deruxte...
The Japanese Ministry of Health approves AstraZeneca's (AZN) Imfinzi plus Imjudo for treating advanced liver cancer and lung cancer.
The European Commission approves AstraZeneca's (AZN) two key cancer drugs Lynparza and Imfinzi for expanded use.